TITLE: Precautionary Period for the Safe Handling of Excreta or Body Fluids in Patients Receiving Cytotoxic or Antineoplastic Therapy: Clinical Evidence and Guidelines

DATE: 27 May 2013

RESEARCH QUESTIONS

1. What is the clinical evidence for the timeframe of the precautionary period for patients receiving cytotoxic or antineoplastic therapy, with regard to the safe handling of excreta, blood products, or other bodily fluids?

2. What are the evidence-based guidelines for the timeframe of the precautionary period for patients receiving cytotoxic or antineoplastic therapy, with regard to the safe handling of excreta, blood products, or other bodily fluids?

KEY MESSAGE

No relevant health technology assessments, systematic reviews, meta-analyses, or evidence-based guidelines were identified regarding the timeframe of the precautionary period for patients receiving cytotoxic or antineoplastic therapy, with regard to the safe handling of excreta, blood products, or other bodily fluids.

METHODS

A limited literature search was conducted on key resources including PubMed, Medline, The Cochrane Library (2013 Issue 4), University of York Centre for Reviews and Dissemination (CRD), Canadian and major international health technology agencies, as well as a focused Internet search. No methodological filters were applied. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2008 and May 16, 2013.
RESULTS

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed evidence-based guidelines.

No relevant health technology assessments, systematic reviews, meta-analyses, or evidence-based guidelines were identified regarding the timeframe of the precautionary period for patients receiving cytotoxic or antineoplastic therapy, with regard to the safe handling of excreta, blood products, or other bodily fluids. References of potential interest are provided in the appendix.

OVERALL SUMMARY OF FINDINGS

No relevant literature was found regarding the timeframe of the precautionary period for patients receiving cytotoxic or antineoplastic therapy, with regard to the safe handling of excreta, blood products, or other bodily fluids; therefore, no summary can be provided.
REFERENCES SUMMARIZED

Health Technology Assessments
No literature identified.

Systematic Reviews and Meta-analyses
No literature identified.

Guidelines and Recommendations
No literature identified.

PREPARED BY:
Canadian Agency for Drugs and Technologies in Health
Tel: 1-866-898-8439
www.cadth.ca
APPENDIX – FURTHER INFORMATION:

Non-Randomized Studies


Guidelines – methodology not stated


Review Articles


Additional References

